Momenta Phama (MNTA) Reports Q2 Loss Per Share of 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Goldman Sachs Downgrades Momenta Pharmaceuticals (MNTA) to Neutral
August 6, 2015 6:59 AM EDTGoldman Sachs downgraded Momenta Pharmaceuticals (NASDAQ: MNTA) from Buy to Neutral with a price target of $27 (unchanged).
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $23.12 yesterday.
... MoreCowen Raises Price Target on Momenta Phama (MNTA) Following 2Q Results
August 5, 2015 9:57 AM EDTCowen reiterated a Market Perform rating on Momenta Pharmaceuticals (NASDAQ: MNTA), and raised the price target to $23.00 (from $18.00), following 2Q results. MNTA reported 2Q EPS of ($0.04) vs consensus of ($0.19).
Analyst Ritu Baral commented, "Investor focus remains Glatopa sales. Early launch looks... More
Momenta Pharmaceuticals (MNTA) PT Raised to $26 at Leerink Partners
August 5, 2015 7:58 AM EDTLeerink Partners analyst Jason Gerberry bumped his price target on Outperform-rated Momenta Pharmaceuticals (NASDAQ: MNTA) to $26.00 (from $25.00) following Q2 results.
Gerberry commented, "... MNTA reported better-than-expected top-line revenue of ~$45m vs our est of ~$7m driven by better-than-expected revenue recognition from Glatopa... More
